Maquet launches pressure control syringe for CABG
Maquet Cardiovascular has launched its Vasoshield pressure controlling syringe that limits “flushing” pressure and controls vessel distension to maintain internal vessel reliability during CABG.

According to the Wayne, N.J.-based company, if pressure is not controlled it has the potential to reach levels of 600 mm Hg, which could create damage to the internal vessel surface.

The Vasoshield syringe has three settings—150, 250 or 350 mm Hg—and pressure can be pre-set in increments for flow delivery during vein preparation, Maquet said.

The company said that the technology is part of the Vasoview product portfolio and is being demonstrated at the American Association of Thoracic Surgeons (AATS) annual meeting May 1-5 in Toronto.